Medpace Holdings Inc vs Verizon Communications Inc — how do they compare? Medpace Holdings Inc trades at $615.17 (market cap $16.82B), while Verizon Communications Inc trades at $41.29 (market cap $192.57B). The key difference: Verizon Communications Inc is far larger — about 11.4× Medpace Holdings Inc's market cap, and Verizon Communications Inc pays a 6.11% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Verizon Communications Inc for 109 Days on average.
| MEDP | VZ | |
|---|---|---|
Market Cap | $16.82B | $192.57B |
Volume | 223,093 | 20,940,094 |
Sector | Health | Media |
52-Week High | $630.19 | $51.45 |
52-Week Low | $393.42 | $38.40 |
Typical Hold Time | 14 Days | 109 Days |
Enterprise Value | $16.44B | $379.28B |
Dividend Yield | — | 6.11% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Verizon (VZ) trades at $41.115, down 10.17% over the past day, reflecting recent market pressure. The stock shows a bearish technical signal with key support at $45. Fundamentally, VZ maintains solid profitability with a 59.26% gross margin and has beaten earnings estimates in recent quarters. The company generates strong operating cash flow of $37.14 billion (2025) and offers a consistent dividend, with recent payouts of $0.71 per share. Analyst consensus is a 'Hold' with a $48.17 price target, indicating potential upside from current levels.
The outlook for VZ hinges on execution in the competitive telecom sector. Opportunities include stable cash flow supporting dividends and joint ventures expanding coverage. Risks involve high debt levels, with total debt at $144.01 billion, and pressure from rivals like T-Mobile. Earnings on October 26, 2026, will be critical for confirming growth trends amid economic uncertainties.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →